FATE - Fate Therapeutics, Inc.
Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors.
As of May 15, 2026: spot at $1.75, ATM IV 147.1%, net GEX $1.6K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $248.2M
- Beta
- 2.14
- 52-Week Range
- 0.91-2.47
- CEO
- Bahram Valamehr
- Employees
- 181
- IPO Date
- Oct 1, 2013
- Exchange
- NASDAQ
What FATE Looks Like to Options Traders Today
IV rank of 27.1% is subdued relative to the 1-year history, conditions that typically favor premium-buying or long-volatility structures (debit spreads, calendar spreads, long straddles); positive net gamma exposure ($1.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-0.494) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The FATE overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked FATE overview questions
- What is FATE?
- FATE is the ticker symbol for Fate Therapeutics, Inc., a listed security. Fate Therapeutics, Inc. , a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Listed on NASDAQ. FATE is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the FATE options snapshot look like today?
- As of May 15, 2026, the FATE options snapshot shows spot at $1.75, ATM IV 147.1%, IV rank 27.1%, net GEX $1.6K, expected move 42.17%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are FATE's key statistics?
- Fate Therapeutics, Inc. (FATE) carries a market capitalization of $248.2M, beta of 2.14 relative to the broader market, 52-week range of 0.91-2.47. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does FATE belong to?
- Fate Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare FATE's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the FATE data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).